Teleflex (NYSE:TFX) Reaches New 52-Week Low - Time to Sell?

Teleflex Incorporated (NYSE:TFX - Get Free Report) shares reached a new 52-week low on Thursday . The stock traded as low as $192.45 and last traded at $192.45, with a volume of 4873 shares changing hands. The stock had previously closed at $193.98.

Analysts Set New Price Targets

TFX has been the topic of several recent research reports. StockNews.com upgraded Teleflex from a "hold" rating to a "buy" rating in a report on Tuesday. Truist Financial reiterated a "hold" rating and issued a $227.00 target price (down previously from $255.00) on shares of Teleflex in a report on Monday, November 4th. Royal Bank of Canada cut their price target on shares of Teleflex from $275.00 to $245.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Mizuho decreased their price objective on shares of Teleflex from $275.00 to $250.00 and set a "neutral" rating for the company in a research note on Friday, November 1st. Finally, Stephens boosted their target price on Teleflex from $275.00 to $290.00 and gave the stock an "overweight" rating in a research note on Friday, August 2nd. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $259.25.

Teleflex Stock Down 1.6 %

The company's fifty day simple moving average is $232.44 and its 200 day simple moving average is $223.53. The company has a quick ratio of 1.39, a current ratio of 2.42 and a debt-to-equity ratio of 0.37. The firm has a market capitalization of $8.86 billion, a PE ratio of 38.17, a price-to-earnings-growth ratio of 2.00 and a beta of 1.18.

Teleflex (NYSE:TFX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The medical technology company reported $3.49 earnings per share for the quarter, topping the consensus estimate of $3.38 by $0.11. The company had revenue of $764.40 million for the quarter, compared to analysts' expectations of $768.68 million. Teleflex had a return on equity of 14.19% and a net margin of 7.85%. The firm's revenue for the quarter was up 2.4% on a year-over-year basis. During the same period in the prior year, the firm earned $3.64 earnings per share. Analysts anticipate that Teleflex Incorporated will post 13.98 earnings per share for the current fiscal year.

Teleflex Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.71%. The ex-dividend date of this dividend is Friday, November 15th. Teleflex's payout ratio is currently 27.04%.

Insider Buying and Selling at Teleflex

In related news, Director Stuart A. Randle sold 2,674 shares of the business's stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $238.93, for a total value of $638,898.82. Following the transaction, the director now directly owns 5,496 shares of the company's stock, valued at approximately $1,313,159.28. The trade was a 32.73 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 1.43% of the stock is owned by company insiders.

Institutional Trading of Teleflex

Institutional investors have recently bought and sold shares of the stock. ProShare Advisors LLC lifted its holdings in shares of Teleflex by 34.1% in the 1st quarter. ProShare Advisors LLC now owns 12,200 shares of the medical technology company's stock worth $2,759,000 after acquiring an additional 3,105 shares during the last quarter. Tidal Investments LLC boosted its position in shares of Teleflex by 214.7% during the first quarter. Tidal Investments LLC now owns 6,644 shares of the medical technology company's stock valued at $1,503,000 after buying an additional 4,533 shares during the period. Boston Trust Walden Corp grew its stake in shares of Teleflex by 2.7% during the second quarter. Boston Trust Walden Corp now owns 233,913 shares of the medical technology company's stock valued at $49,199,000 after buying an additional 6,076 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in shares of Teleflex by 15.8% in the first quarter. Russell Investments Group Ltd. now owns 18,838 shares of the medical technology company's stock worth $4,245,000 after buying an additional 2,570 shares during the period. Finally, Quantbot Technologies LP purchased a new position in Teleflex during the 1st quarter valued at $537,000. 95.62% of the stock is currently owned by institutional investors.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.